Rigel Pharmaceuticals Inc
RIGL—
Build a strategy around RIGL
Rigel Pharmaceuticals Inc AI Insights
Informational only. Not investment advice.Snapshot
- EPS growth of 109% TTM vs industry median of 1.7% - rare profitable biotech with accelerating earnings momentum[EPS Growth 1yr]
- Operating margin 42% TTM vs industry median of 0% - transformed from cash-burning biotech to profit machine[Operating Margin TTM]
- FCF of 68.1M TTM with near-zero capex (38K) - 24% FCF yield on 282M revenue, self-funding growth[Free Cash Flow TTM]
Watch Triggers
- Total Revenue TTM: Decline >10% QoQ — Royalty-dependent model means revenue drop signals partner sales weakness or contract loss
- Operating Margin TTM: Falls below 30% — Would indicate R&D ramp or pricing pressure eroding profit engine
- Cash and Equivalents: Falls below 30M — With 29.8M current debt, liquidity squeeze could force dilutive financing
Bull Case
Rare profitable biotech: 42% operating margin, 59% ROA, 24% FCF yield - metrics typically seen in mature tech, not pharma
Operating Margin TTMROA TTMFree Cash Flow TTM
P/E of 7.1x vs industry median 20.2x despite 109% EPS growth - valuation disconnect if earnings sustainable
PE RatioEPS Growth 1yr
Bear Case
Revenue concentration risk: 282M total revenue likely from 1-2 drugs; patent cliffs or competition could collapse earnings
Total Revenue TTM
Debt of 60.9M (0.52x equity) with 7.6M interest expense; current debt of 29.8M due near-term vs 48.5M cash
Total DebtCurrent DebtCash and Equivalents
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
55%
Leverage RIGL's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Margin expansion sustainable as royalty/licensing revenue scales with minimal incremental cost
1-3ymed
- Gross margin 93% indicates royalty-heavy revenue mix
- R&D at 28M (10% of revenue) vs 37M industry median
- Operating leverage: 46% 3yr revenue CAGR driving 109% EPS growth
Operating margin 42% vs 0% industry median TTMNet margin 40% TTM with minimal capex needsROA 59% TTM vs -32% industry median
Valuation Context
Caveats
RIGL Fundamentals
Manufacturing → Chemical Manufacturing
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$484.75M | — | ||
$506.06M | — | ||
1.4 | — | ||
$299.77M | +47.6% | — | |
$19.29 | +823.0% | — | |
41.6% | +19.9% | — | |
122% | +103.2% | — | |
$79.27M | +124.4% | — | |
174% | — | ||
Beta 5Y (Monthly) | unknown | — |
RIGL Dividend History
No dividends
RIGL Stock Splits
2 stock splits
06/27/2410:1 split
06/25/039:1 split
RIGL SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/05/26 | 03/31/26 | 10-Q | |
03/03/26 | 12/31/25 | 10-K | |
11/04/25 | 09/30/25 | 10-Q | |
08/05/25 | 06/30/25 | 10-Q | |
05/06/25 | 03/31/25 | 10-Q | |
03/04/25 | 12/31/24 | Unknown | |
11/07/24 | 09/30/24 | 10-Q | |
08/06/24 | 06/30/24 | 10-Q | |
05/07/24 | 03/31/24 | 10-Q | |
03/05/24 | 12/31/23 | 10-K | |
11/07/23 | 09/30/23 | 10-Q | |
08/01/23 | 06/30/23 | 10-Q | |
05/02/23 | 03/31/23 | 10-Q | |
03/07/23 | 12/31/22 | 10-K | |
11/03/22 | 09/30/22 | 10-Q | |
08/02/22 | 06/30/22 | 10-Q | |
05/03/22 | 03/31/22 | 10-Q | |
03/01/22 | 12/31/21 | 10-K | |
11/02/21 | 09/30/21 | 10-Q | |
08/03/21 | 06/30/21 | 10-Q | |
05/05/21 | 03/31/21 | 10-Q | |
03/02/21 | 12/31/20 | 10-K | |
11/05/20 | 09/30/20 | 10-Q | |
08/04/20 | 06/30/20 | 10-Q | |
05/05/20 | 03/31/20 | 10-Q | |
02/27/20 | 12/31/19 | 10-K | |
11/05/19 | 09/30/19 | 10-Q | |
08/06/19 | 06/30/19 | 10-Q | |
05/07/19 | 03/31/19 | 10-Q | |
02/28/19 | 12/31/18 | 10-K | |
11/06/18 | 09/30/18 | 10-Q | |
08/08/18 | 06/30/18 | 10-Q | |
05/01/18 | 03/31/18 | 10-Q | |
03/06/18 | 12/31/17 | 10-K | |
11/07/17 | 09/30/17 | 10-Q | |
08/01/17 | 06/30/17 | 10-Q | |
05/02/17 | 03/31/17 | 10-Q | |
03/07/17 | 12/31/16 | 10-K | |
11/01/16 | 09/30/16 | 10-Q | |
08/02/16 | 06/30/16 | 10-Q | |
05/03/16 | 03/31/16 | 10-Q | |
03/08/16 | 12/31/15 | 10-K | |
11/03/15 | 09/30/15 | 10-Q | |
08/04/15 | 06/30/15 | 10-Q | |
05/07/15 | 03/31/15 | 10-Q | |
03/03/15 | 12/31/14 | 10-K | |
11/04/14 | 09/30/14 | 10-Q | |
08/05/14 | 06/30/14 | 10-Q | |
05/07/14 | 03/31/14 | 10-Q | |
03/04/14 | 12/31/13 | 10-K | |
11/05/13 | 09/30/13 | 10-Q | |
08/06/13 | 06/30/13 | 10-Q | |
05/07/13 | 03/31/13 | 10-Q | |
03/05/13 | 12/31/12 | 10-K | |
11/06/12 | 09/30/12 | 10-Q | |
08/07/12 | 06/30/12 | 10-Q | |
05/01/12 | 03/31/12 | 10-Q | |
03/06/12 | 12/31/11 | 10-K | |
11/01/11 | 09/30/11 | 10-Q | |
08/02/11 | 06/30/11 | 10-Q | |
05/03/11 | 03/31/11 | 10-Q | |
03/01/11 | 12/31/10 | 10-K | |
11/01/11 | 09/30/10 | 10-Q | |
08/03/10 | 06/30/10 | 10-Q | |
05/04/10 | 03/31/10 | 10-Q | |
03/02/10 | 12/31/09 | 10-K | |
11/02/10 | 09/30/09 | 10-Q | |
11/03/09 | 09/30/09 | 10-Q | |
08/04/09 | 06/30/09 | 10-Q | |
05/05/09 | 03/30/09 | 10-Q | |
02/27/09 | 12/31/08 | 10-K | |
11/04/08 | 09/30/08 | 10-Q | |
08/05/08 | 06/30/08 | 10-Q | |
05/06/08 | 03/30/08 | Unknown | -- |
03/07/08 | 12/31/07 | 10-K | |
11/06/07 | 09/30/07 | 10-Q | |
08/07/07 | 06/30/07 | 10-Q | |
05/10/07 | 03/30/07 | Unknown | -- |
03/08/07 | 12/31/06 | 10-K | |
11/07/06 | 09/30/06 | 10-Q | |
08/02/06 | 06/30/06 | 10-Q | |
05/03/06 | 03/30/06 | Unknown | -- |
03/08/06 | 12/31/05 | 5 | |
11/08/05 | 09/30/05 | 10-Q | |
08/05/05 | 06/30/05 | 10-Q | |
05/06/05 | 03/30/05 | Unknown | -- |
03/16/05 | 12/31/04 | 10-K | |
11/05/04 | 09/30/04 | 10-Q | |
08/09/04 | 06/30/04 | 10-Q | |
05/10/04 | 03/30/04 | Unknown | -- |
03/12/04 | 12/31/03 | 8-K | |
11/14/03 | 09/30/03 | 10-Q | |
08/14/03 | 06/30/03 | 10-Q | |
05/15/03 | 03/30/03 | Unknown | -- |
03/31/03 | 12/31/02 | 10-K | |
11/14/02 | 09/30/02 | 4 | |
08/14/02 | 06/30/02 | 10-Q | |
05/14/02 | 03/30/02 | Unknown | -- |
03/29/02 | 12/31/01 | 10-K405 | |
11/13/01 | 09/30/01 | 10-Q | |
08/14/01 | 06/30/01 | 10-Q | |
05/14/01 | 03/30/01 | Unknown | -- |
03/30/01 | 12/31/00 | 10-K405 | |
09/30/00 | 09/30/00 | Unknown | -- |
06/30/00 | 06/30/00 | Unknown | -- |
03/31/00 | 03/30/00 | Unknown | -- |